Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 5
2005 2
2006 4
2007 1
2008 3
2009 6
2010 3
2011 4
2012 5
2013 14
2014 8
2015 11
2016 15
2017 21
2018 21
2019 24
2020 28
2021 22
2022 26
2023 21
2024 19
2025 19
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

251 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
Erratum.
Hu W, Lu Z, Meng F, Li X, Cong R, Ren T, Sharkey TD, Lu J. Hu W, et al. Among authors: lu j. New Phytol. 2021 Sep;231(6):2398. doi: 10.1111/nph.17472. Epub 2021 Aug 13. New Phytol. 2021. PMID: 34390258 Free article. No abstract available.
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
Liu T, Bai Y, Lin X, Li W, Wang J, Zhang X, Pan H, Bai C, Bai L, Cheng Y, Zhang J, Zhong H, Ba Y, Hu W, Xu R, Guo W, Qin S, Yang N, Lu J, Shitara K, Lei M, Li M, Bao N, Chen T, Shen L. Liu T, et al. Among authors: lu j. Int J Cancer. 2023 Feb 15;152(4):749-760. doi: 10.1002/ijc.34296. Epub 2022 Oct 31. Int J Cancer. 2023. PMID: 36121651 Free PMC article. Clinical Trial.
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.
Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, Zhang X, Fan N, Luo S, Li Z, Gu K, Lu J, Xu J, Fan Q, Xu R, Zhang L, Li E, Sun Y, Yu G, Bai C, Liu Y, Zeng J, Ying J, Liang X, Xu N, Gao C, Shu Y, Ma D, Dai G, Li S, Deng T, Cui Y, Fang J, Ba Y, Shen L. Peng Z, et al. Among authors: lu j. Cancer Commun (Lond). 2021 Nov;41(11):1173-1182. doi: 10.1002/cac2.12214. Epub 2021 Oct 19. Cancer Commun (Lond). 2021. PMID: 34665942 Free PMC article. Clinical Trial.
miR-449a: a potential therapeutic agent for cancer.
Yong-Ming H, Ai-Jun J, Xiao-Yue X, Jian-Wei L, Chen Y, Ye C. Yong-Ming H, et al. Anticancer Drugs. 2017 Nov;28(10):1067-1078. doi: 10.1097/CAD.0000000000000555. Anticancer Drugs. 2017. PMID: 29023247 Review.
A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer.
Li N, Qiu M, Zhang Y, Yang M, Lu L, Li W, Ma Y, Hou X, Sun G, Cai M, Wang J, Lu J, Zhong D, Huo Z, Zhang J, Yin X, Deng J, Liu Z, Pan H, Chen Y, Yang F, Yu H, Li J, Wang Q, Zhu J, Li J. Li N, et al. Among authors: lu j. Med. 2024 Oct 11;5(10):1255-1265.e2. doi: 10.1016/j.medj.2024.06.004. Epub 2024 Jul 9. Med. 2024. PMID: 38986608 Free article. Clinical Trial.
Cross-Modal Prostate Cancer Segmentation via Self-Attention Distillation.
Zhang G, Shen X, Zhang YD, Luo Y, Luo J, Zhu D, Yang H, Wang W, Zhao B, Lu J. Zhang G, et al. Among authors: lu j. IEEE J Biomed Health Inform. 2022 Nov;26(11):5298-5309. doi: 10.1109/JBHI.2021.3127688. Epub 2022 Nov 10. IEEE J Biomed Health Inform. 2022. PMID: 34767517
251 results